All News
Filter News
Found 50 articles
-
Data at the 2022 ASCO Annual Meeting Highlight Genentech’s Continued Commitment to Innovation in Oncology and Personalized Healthcare
5/24/2022
Genentech, a member of the Roche Group, announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Oncology Annual Meeting, which will be held June 3-7, 2022.
-
Hemlibra Sales Driving Global Bispecific Antibodies Market
5/11/2022
Hemlibra is bispecific antibody which restores the hemostatic process and indicated for the routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patient’s ages newborn and older with hemophilia A with or without factor VIII inhibitors.
-
Swiss pharma giant Roche predicts a revenue slowdown related to its COVID-19 products and the increasing challenge of biosimilar drugs.
-
Epizyme Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
3/1/2022
Epizyme today reported fourth quarter and full year 2021 financial results and provided business and portfolio updates.
-
Fate Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Operational Progress
2/28/2022
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2021.
-
Biogen announced it was exercising its option to participate in Genentech’s development of mosunetuzumab under a long-standing collaboration for antibodies targeting CD20.
-
Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody
2/1/2022
Biogen Inc. (Nasdaq: BIIB) today announced that it exercised its option to participate in the development and commercialization of mosunetuzumab.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
City of Hope presents leading-edge research on blood cancer therapies and its vaccine to reduce stem cell transplant complications at American Society of Hematology (ASH) Annual Meeting
12/16/2021
City of Hope doctors presented data on an investigational bispecific antibody for multiple myeloma and the CMVPepVax, a City of Hope-developed vaccine against the cytomegalovirus, at this year’s ASH Annual Meeting.
-
Genentech’s Polivy Combination Reduced the Risk of Disease Worsening or Death by 27% in People With Previously Untreated Aggressive Form of Lymphoma
12/14/2021
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the Phase III POLARIX study showing that treatment with Polivy® (polatuzumab vedotin) in combination with Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP).
-
Genentech Presents Pivotal Data at ASH 2021 for Novel Cancer Immunotherapy Mosunetuzumab
12/11/2021
Genentech, a member of the Roche Group, announced that new pivotal data on its CD20xCD3 T-cell engaging bispecific antibody, mosunetuzumab, will be presented for the first time at the 63rd American Society of Hematology Annual Meeting & Exposition from December 11-14, 2021.
-
Pivotal Study Led by City of Hope Shows First-in-Class Cancer Immunotherapy Achieves High Rate of Remission in Patients With a Type of Non-Hodgkin Lymphoma
12/11/2021
City of Hope announced that data from an investigational Phase 1/2, single arm trial using a bispecific antibody called mosunetuzumab highlights the paradigm-changing potential of a new treatment option for people with follicular lymphoma, a type of blood cancer and the most common indolent form of non-Hodgkin lymphoma.
-
New Studies Highlight How Immunotherapies Are Transforming Care for Blood Cancers
12/11/2021
Four studies being presented during the 63rd American Society of Hematology Annual Meeting and Exposition point to the transformative role immunotherapies are playing in the treatment of major blood cancers.
-
Genentech to Present New Pivotal Data at ASH 2021 From Broad and Comprehensive Portfolio, Challenging Treatment Standards for People With Blood Disorders
11/23/2021
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its extensive hematology portfolio will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition from December 11-14, 2021.
-
City of Hope Doctors Present New Research on Cancer Immunotherapies
11/4/2021
New data on bispecific antibodies and stem cell transplants will be presented in person and virtually at the American Society of Hematology Annual Meeting Dec. 11 to 14.
-
Phase III Study Shows Genentech's Polivy Plus R-CHP Is the First Regimen in 20 Years to Significantly Improve Outcomes in Previously Untreated Aggressive Form of Lymphoma Compared to Standard of Care
8/9/2021
Genentech, a member of the Roche Group, announced that the pivotal Phase III POLARIX trial investigating Polivy® in combination with Rituxan® plus cyclophosphamide, doxorubicin and prednisone versus Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone met its primary endpoint by demonstrating significantly improved and clinically meaningful progression-free survival in people with previously untreated diffuse large B-cell lymphoma.
-
BioSpace caught up with Charles Fuchs, M.D., SVP, Global Head of Oncology & Hematology Product Development, Genentech during the ASCO meeting on personalized cancer care.
-
Genentech Presents Latest Advances With Immunotherapies in Non-Hodgkin’s Lymphoma
6/4/2021
– Data for investigational CD20xCD3 bispecific antibodies and new combination regimens with Polivy showed enhanced clinical benefits for people with non-Hodgkin’s lymphoma in early studies –
-
Genentech to Present Data From One of the Most Comprehensive Oncology Portfolios at the 2021 ASCO Annual Meeting Showcasing Advancements for People Living With Cancer
5/11/2021
Studies in personalized healthcare exploring tumor agnostic treatments that demonstrate the impact of coupling biomarker testing with targeted therapies to develop individualized treatment plans
-
Erasca Appoints Michael Varney, Ph.D., to its Board of Directors
12/18/2020
Erasca, a company whose mission is to erase cancer, announced the appointment of Michael Varney, Ph.D., to its board of directors